科技部:“生物医用材料研发与组织器官修复替代”重点专项征求意见

2019-03-29 佚名 科技部

日前,科技部发布《关于国家重点研发计划“生物医用材料研发与组织器官修复替代”重点专项2019年度项目申报指南征求意见的通知》。

日前,科技部发布《关于国家重点研发计划“生物医用材料研发与组织器官修复替代”重点专项2019年度项目申报指南征求意见的通知》。

附全文

“生物医用材料研发与组织器官修复替代”重点专项2019年度项目申报指南

(征求意见稿)

“生物医用材料研发与组织器官修复替代”重点专项旨在面向国家发展大健康产业和转变经济发展方式对生物医用材料的重大战略需求,把握生物医用材料科学与产业发展的趋势和前沿,抢抓生物医用材料革命性变革的重大机遇,充分利用我国生物医用材料科学与工程研究方面的基础和优势,以新型骨骼—肌肉系统、血管系统材料、植入器械及高值医用耗材为重点,开发一批新产品,突破一批关键技术,培育一批具有国际竞争力的高集中度多元化生产的龙头企业以及创新团队,构建我国新一代生物医用材料产业体系,引领生物医用材料产业技术进步,为我国生物医用材料产业跻身国际先进行列提供科技支撑。

目前专项已启动三批项目立项,涉及前沿科学及基础创新、关键核心技术、产品开发、典型示范4大研究任务,以及涉及前沿科学及基础创新、关键核心技术、产品开发、典型示范等的医用级原材料的研发及产业化、标准和规范研究、临床临床转化研究3项重点任务。已部署国拨经费8.2963亿元。

上述项目的部署,有力推进了我国在骨科、心脑血管、神经修复、眼科、口腔等疾病领域的植介入器械的发展,推动相关领域的临床及临床转化研究。然而,由于医用级基础原材料严重依赖进口,前沿创新产品开发不足的问题仍然突出。进一步解决我国医用级基础原材料严重依赖进口、临床急需的创新产品开发不足等问题,本批指南重点聚焦生物医用材料领域原材料和前沿创新产品开发,2019年拟在医用级原材料的研发及产业化、植/介入医用导管及器械表面改性核心关键技术及临床急需新型医疗器械产品研发等研究方向部署项目。国拨经费约为0.7亿元。实施周期为2019—2021年。

1.医用级原材料的研发与标准研究及产业化

1.1医用聚氨酯热塑性弹性体和交联超高分子量聚乙烯原材料研发、技术提升与改进及产业化

研究内容:研发耐水解耐氧化医用导管用聚氨酯热塑性弹性体和人工关节用交联超高分子量聚乙烯原材料及成型加工和产业化生产技术。

考核指标:聚氨酯热塑性弹性体及交联超高分子量聚乙烯质量参数达到国际同类医用级原材料质量标准;其它化学和生物学性能指标满足相关国家和行业标准要求。形成规模化生产能力,开发留置与介入类医疗器械的2个系列产品;获得核心发明专利8-12项;建立聚氨酯热塑性弹性体和交联超高分子量聚乙烯原材料质量标准;提供医用级原材料第三方检测报告,形成的棒料应达到国际标准。

拟支持项目数:1~2项。

有关说明:要求产、学、研联合申报,且其他经费(包括地方财政经费、单位出资及社会渠道资金等)与中央财政经费比例不低于3:1。

1.2 医用聚醚醚酮材料研发及产业化关键技术研究

研究内容:研发医用聚醚醚酮(Polyether-ether-ketone,PEEK)材料及成型加工和产业化生产技术。

考核指标:研发的PEEK材料应符合GB/T16886系列标准及相关外科植入物用PEEK的标准规范,主要性能不低于进口医用PEEK材料;获得核心发明专利5项;建立PEEK原材料质量标准;提供医用级原材料第三方检测报告。建成年产500公斤级医用PEEK材料原料生产装置,同时制备至少1种植入体内骨科产品,并进入临床试验。

拟支持项目数:1~2项。

有关说明:要求产、学、研联合申报,且其他经费(包括地方财政经费、单位出资及社会渠道资金等)与中央财政经费比例不低于3:1。

1.3心血管支架用合金细径薄壁管材研发及产业化技术

研究内容:开展心血管支架用CoCr基、TiNi基合金铸锭质量优化,管坯的温、热加工及显微组织及力学性能研究,管材的冷加工成型和显微组织和力学性能调控,以及表面处理、缺陷分析及在线无损检测技术研究,解决心血管支架用合金细径薄壁管材的国产化问题。

考核指标:研发心血管支架用合金细径薄壁管材,其外壁、表面粗糙度、管材弯曲度等技术参数达到国际同类产品标准;管材组织均匀,晶粒度8级以上;其抗拉强度≥1000MPa,延伸率≥10%;其杂质元素符合国际标准;生物相容性符合GB/T16886标准要求,提供医用级原材料第三方检测报告,建成年产各10吨的生产装置,同时制备至少1种植入体内血管支架产品,并进入临床试验。

拟支持项目数:1~2项。

有关说明:要求具有非铁金属加工企业牵头并结合血管支架生产企业联合申报,具有前期研究基础;且其他经费(包括地方财政经费、单位出资及社会渠道资金等)与中央财政经费比例不低于3:1。

2.关键核心技术

2.1植/介入医用导管及器械表面超亲水超润滑改性研究

研究内容:研究心血管系统、泌尿系统、消化系统、呼吸系统、生殖系统的植/介入导管及器械的表面超亲水超润滑改性材料与工程化技术,开发具有表面抗阻、抗菌和防组织粘连的多功能的医用导管和医疗器械产品。

考核指标:突破 4~5 种植/介入医用导管或器械表面的超亲水超润滑、抗菌和防黏连改性等关键工程化技术,开发系列超亲水超润滑涂层材料,用于输注类、介入治疗及管腔替换等医用导管。无细胞毒性、无过敏刺激反应,较长期(大于30 天)存留于体内,涂层稳定,无剥落,保持超润滑,摩擦力小于0.5N,且无感染,无组织粘连发生。申请或获得 NMPA医疗器械新产品注册证 3 项以上,获得核心发明专利 8 项以上。

拟支持项目数:1~2项。

有关说明:要求企业牵头申报,鼓励产、学、研、医联合,其他经费(包括地方财政经费、单位出资及社会渠道资金等)与中央财政经费比例不低于3:1。

2.2用于骨质疏松治疗的纳米生物材料制备的工程化技术及临床应用技术

研究内容:研究纳米生物材料的纳米生物学效应,重点突破可促进成骨细胞增殖和诱导骨再生的纳米生物材料的设计和制备的工程化技术;设计用于骨质疏松预防和治疗的新剂型,研发其制备及临床应用技术;建立疗效和风险评价的模型和方法。

考核指标:针对目标疾病,开发不少于1款国际原创或国内首创具有自主知识产权的产品,及其工程化制备和临床应用技术;植入动物骨质疏松部位后4周新骨开始形成,16周左右强度可接近松质骨水平;研究制定产品技术要求,研发微创植入器械,国内首创产品性能不低于国外同类产品水平;2021年底前申请或获得至少1个医疗器械产品注册证;获得核心发明专利3项以上。

拟支持项目数:1~2项。

有关说明:要求企业牵头申报,产、学、研、医结合,并有前期研究基础,其他经费(包括地方财政经费、单位出资及社会渠道资金等)与中央财政经费比例不低于3:1。

3. 前沿创新产品开发

3.1多孔钽骨修复材料及植入性产品开发

研究内容:开展多孔钽材料构效关系的深入研究;不同用途多孔钽骨科植入产品和口腔修复植入产品的设计;多孔钽结构与性能的精准调控及一体化制备技术研发;体内修复功能(支撑、组织再生、骨整合等)评价及优化;临床试验及临床疗效评价。研究综合利用注册检验大数据分析等方式,开展人工智能验证性分析和评价。

考核指标:开发出5种以上针对不同用途的一体化结构多孔钽骨科植入产品及口腔修复植入产品,其中:个性化定制产品不少于3种,国际原创或国内首创具有自主知识产权的产品不少于2种;建立产品体内外安全性和有效性检测技术,突破工程化制备技术,建立符合GMP要求的生产质量体系,建立3个个性化定制植入器械生物等效性模型及验证体系;以循证医学和流行病学技术研究建立个性化定制式植入器械临床试验模型和术后跟踪新方法。确定个性化产品质量控制关键点和评价指标,建立相应检验方法,形成相关产品技术规范;建立个性化匹配植入器械同类产品检验数据库2个;申请或获得发明专利10项以上;2021年底至少2种产品获得NMPA医疗器械注册证。

拟支持项目数:1~2项。

3.2儿童骨缺损再生植入器械开发及临床应用方案研究

研究内容:针对儿童颅、颌面和干骨段缺损的重大损伤或病变,研发适用于儿童骨再生的个性化骨植入器械,以及骨再生器械的临床植入技术,解决常规骨植入器械不能适应儿童骨发育过程中骨骼长大的问题。

考核指标:针对目标疾病,开发不少于1款国际原创或国内首创具有自主知识产权的产品,植入材料和原骨界面可于1-2周内再生新骨且紧密结合,3-6月植入器械强度可达相应部位宿主骨强度的60-80%;开发示范性临床植入手术;2021年底前申请或获得医疗器械产品注册证;建立符合GMP要求的批量生产线,申请或获得发明专利不少于5项。

拟支持项目数:1~2项。

3.3主动脉腔内治疗器械开发及临床应用方案研究

研究内容:针对高外科手术风险的主动脉瘤与夹层等疾病,开发新型全主动脉腔内治疗器械,研究制定产品技术要求,建立产品临床操作规范,形成创新型产品和临床应用方案。

考核指标:针对目标疾病,开发不少于1款国际原创或国内首创具有自主知识产权的产品,新产品应满足主动脉腔内重建分支血管要求,适应证范围能够覆盖绝大部分主动脉疾病;产品放置成功率达到90%以上,内漏发生率在10%以内;建立产品临床操作规范;2021年底前申请或获得医疗器械产品注册证;申请或获得发明专利不少于5项。

拟支持项目数:1~2项。

3.4经导管肺动脉瓣膜置换系统开发及临床应用方案研究

研究内容:针对肺动脉反流和肺动脉狭窄两种治疗需求,开发具备抗凝血、耐久度高、输送系统尺寸小的生物瓣膜产品;研究制定产品技术要求,建立产品临床操作规范,形成创新型产品和临床应用方案。

考核指标:针对目标疾病,研制出24Fr以下的治疗肺动脉瓣膜返流和狭窄的经导管肺动脉瓣膜置换系统,抗钙化及抗凝血效果比传统处理提高40%以上,耐久性能比传统瓣膜提高50%以上;建立产品临床操作规范;2021年底前申请或获得医疗器械产品注册证;申请或获得发明专利不少于8项。

拟支持项目数:1~2项。

3.5重度感染或重症免疫性疾病治疗性血液净化产品开发及临床应用方案研究

研究内容:针对重度感染或重症免疫性疾病(如自身免疫性脑炎、扩张型心肌病、器官移植排斥反应等),开展固定化酶、血液滤过吸附、致病抗体靶向清除等新技术研究,研发新型治疗性血液净化材料与血液净化装置。

考核指标:针对目标疾病,开发不少于1款国际原创或国内首创具有自主知识产权的产品;血液净化所使用的医用生物高分子微球吸附载体材料和蛋白A配基材料实现自主可控,关键质量参数达到国际同类产品水平,实现产业化;2021年底前申请或获得医疗器械产品注册证;申请或获得发明专利不少于5项

拟支持项目数:1~2项。

有关说明:以上前沿创新产品开发类项目均要求企业牵头申报,鼓励产、学、研、医、检联合。中央财政经费以小额资助为主,鼓励社会资本参与投入,其他经费(包括地方财政经费、单位出资及社会渠道资金等)与中央财政经费比例不低于3:1。每个项目针对1个产品进行申报,所申报的产品为原创产品,有较好的前期研究基础,其核心技术已获得发明专利或进入专利实质性审查阶段,应已完成有效性和安全性评价,具有显着的临床应用价值。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]
    2019-03-31 lqvr
  7. [GetPortalCommentsPageByObjectIdResponse(id=2034483, encodeId=2c70203448346, content=<a href='/topic/show?id=07b8e7668b8' target=_blank style='color:#2F92EE;'>#组织器官#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77668, encryptionId=07b8e7668b8, topicName=组织器官)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Dec 08 19:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1719415, encodeId=778b1e19415f0, content=<a href='/topic/show?id=d970958e600' target=_blank style='color:#2F92EE;'>#重点专项#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95876, encryptionId=d970958e600, topicName=重点专项)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c65032711327, createdName=zhmscau, createdTime=Mon Aug 05 14:51:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986231, encodeId=e84819862314f, content=<a href='/topic/show?id=2098692569c' target=_blank style='color:#2F92EE;'>#生物医用材料#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69256, encryptionId=2098692569c, topicName=生物医用材料)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Sat Nov 16 03:51:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949933, encodeId=c78c194993379, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Nov 22 12:51:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798496, encodeId=596a1e984969f, content=<a href='/topic/show?id=ba9b69255bf' target=_blank style='color:#2F92EE;'>#生物医用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69255, encryptionId=ba9b69255bf, topicName=生物医用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Apr 13 06:51:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300251, encodeId=a40b13002517e, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487696, encodeId=e9fb148e69600, content=<a href='/topic/show?id=c00de49752c' target=_blank style='color:#2F92EE;'>#科技部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74975, encryptionId=c00de49752c, topicName=科技部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe118348559, createdName=liubm558, createdTime=Sun Mar 31 03:51:00 CST 2019, time=2019-03-31, status=1, ipAttribution=)]

相关资讯

生物医用材料国内外产业现状和发展趋势

生物医用材料(Biomedical Materials),是用来对生物体进行诊断、治疗、修复或替换其病损组织、器官或增进其功能的材料。生物医用材料基本情况生物医用材料作为一种研究人工器官和医疗器械的基础,生物医用材料现在已经成为了当代材料学科的重要分支,尤其是随着生物技术的蓬勃发展和重大突破,生物医用材料已经成为了各国科学家竞相进行研究和开发的热点,近几年来,有关医用材料以及医用材料在高新医疗

“生物医用材料研发与组织器官修复替代”重点专项2016年度申报指南

随着生命科学、材料科学及物理、化学等学科的发展,特别是组织工程技术的发展,推动人体组织器官的修复替代进入了一个崭新的阶段。在我国人口老龄化的加速演进的新形势下,加快研发生物医用材料和组织工程技术及产品,对于培育我国战略新兴产业,转变经济发展方式,实现科技惠及民生具有重要战略意义。 为全面落实《国家中长期科学和技术发展规划纲要(2006-2020年)》的相关任务,按照国务院《关于深化中央财